Free Trial
NASDAQ:ANEB

Anebulo Pharmaceuticals Q2 2025 Earnings Report

Anebulo Pharmaceuticals logo
$0.46 +0.00 (+0.54%)
As of 03:05 PM Eastern

Anebulo Pharmaceuticals EPS Results

Actual EPS
-$0.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Anebulo Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anebulo Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Friday, February 14, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Anebulo Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, May 7, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, May 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Anebulo Pharmaceuticals Earnings Headlines

Anebulo Pharmaceuticals (ANEB) Projected to Post Earnings on Thursday
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.tc pixel
See More Anebulo Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anebulo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anebulo Pharmaceuticals and other key companies, straight to your email.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals (NASDAQ:ANEB) (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S. Food and Drug Administration upon completion of these studies. Anebulo has established manufacturing and distribution strategies to support future commercialization, aiming to deliver a differentiated option for patients who require fast-acting, non-oral migraine relief.

Founded in 2019 and headquartered in Campbell, California, Anebulo Pharmaceuticals brings together a team of industry veterans in drug delivery and neurology. By leveraging proprietary intranasal delivery technology, the company seeks to address unmet needs in migraine care and expand its development pipeline in related therapeutic areas.

View Anebulo Pharmaceuticals Profile